The Safety And Efficacy Of Maintenance Therapy With CP-690,550
- Registration Number
- NCT01393899
- Lead Sponsor
- Pfizer
- Brief Summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 180
- Subjects who met study entry criteria, and who completed Week 8 visit of Induction Study A3921083.
- Subjects who achieve clinical response-100 (reduction in CDAI by 100 points) and/or clinical remission (CDAI<150) in Study A3921083.
- Women of childbearing potential must test negative for pregnancy prior to study enrolment.
- Subjects who had major protocol violation (as determined by the Sponsor) in the A3921083 study.
- Subjects likely to require any type of surgery during the study period.
- Fecal culture/toxin assay indicating presence of pathogenic infection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo BID Placebo - 5mg BID CP-690,550 - 10mg BID CP-690,550 -
- Primary Outcome Measures
Name Time Method Percentage of Participants With Clinical Response-100 (as Defined by a Decrease in Crohn's Disease Activity Index [CDAI] Score of at Least 100 Points From Baseline) or Clinical Remission (CDAI Score Less Than [<]150) at Week 26 Week 26 Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of a weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI score was based partly on entries (7 days before evaluation) from participant's diary kept while on study. CDAI scores range from 0 to approximately 600, higher score indicates higher disease activity.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Sustained Clinical Response-100 (Defined as Having at Least a Clinical Response-100 at Both Weeks 20 and 26 From the A3921083 Baseline) in the Maintenance Phase Weeks 20 and 26 Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
CDAI Score by Week Baseline and Weeks 4, 8, 12, 20 and 26 CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity
Change From Baseline in CDAI Score by Week Weeks 4, 8, 12, 20 and 26 CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity
Kaplan-Meier Estimate of the Rate of Time to Relapse Weeks 4, 8 12, 20 and 26 Time to relapse was defined as increase in CDAI of more than (\>)100 points from the maintenance phase baseline and a CDAI score of \>220 points, or an increase to or above the baseline CDAI score in A3921083. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Percentage of Participants Achieving a Steroid-Free Clinical Remission at Week 26 of the Maintenance Phase - Among Participants on Steroids at A3921084 Baseline Week 26 Clinical remission was a CDAI \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general wellbeing, occurrence of extraintestinal symptoms, need for antidiarrheal drugs, presence of abdominal masses, hematocrit, and body eight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
C-Reactive Protein (CRP) by Week Baseline and Weeks 4, 8, 12, 20 and 26 The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Change From Baseline in CRP by Week Weeks 4, 8, 12, 20 and 26 The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Fecal Calprotectin by Week Baseline and Weeks 8, 12 and 26 Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
Change From Baseline in Fecal Calprotectin by Week Weeks 8, 12 and 26 Fecal calprotectin is an inflammatory marker for the gastrointestinal tract and considered as a measurement of neutrophil migration to the gastrointestinal tract. Higher values indicate more serious inflammation.
Tofacitinib Plasma Concentration by Nominal Post-Dose Sampling Time and Tofacitinib Dose Pre-dose, 20 minutes, 40 minutes, 1 hour and 2 hours post-dose at Weeks 12 and 26/early termination visit Plasma samples were collected from participants for the determination of tofacitinib concentrations. Only samples from tofacitinib-treated participants were subsequently analyzed. Plasma concentration data are summarized by nominal sample collection times specified in the protocol, and actual sample collection times may be different.
Percentage of Participants With Clinical Response-100 or Clinical Remission at Weeks 4, 8, 12 and 20 Weeks 4, 8, 12 and 20 Clinical response-100 was defined as a reduction in CDAI score of at least 100 points from baseline of the parent A3921083 study. Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Percentage of Participants Achieving Clinical Response-100 at Weeks 4, 8, 12, 20 and 26 Weeks 4, 8, 12, 20 and 26 Clinical response-100 was defined as a reduction in CDAI score from baseline of at least 100 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Percentage of Participants in Clinical Remission at Weeks 4, 8, 12, 20 and 26 Weeks 4, 8, 12, 20 and 26 Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Percentage of Participants in Clinical Remission at Week 4, 8, 12, 20 and 26 Among Participants in Remission at Baseline of Maintenance Study Weeks 4, 8, 12, 20 and 26 Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Percentage of Participants in Sustained Clinical Remission (Defined as Being in Clinical Remission at Both Weeks 20 and 26) in the Maintenance Phase Weeks 20 and 26 Clinical remission was a CDAI score \<150 points. CDAI is a composite index consisting of weighted scoring of 8 disease variables: number of liquid or very soft stools, extent of abdominal pain, general well-being, occurrence of extraintestinal symptoms, need for anti-diarrheal drugs, presence of abdominal masses, hematocrit, and body weight. CDAI scores range from 0 to approximately 600 points, higher score indicates higher disease activity.
Trial Locations
- Locations (91)
Monash Medical Centre
🇦🇺Clayton, Victoria, Australia
Pannonia Magánorvosi Centrum Kft
ðŸ‡ðŸ‡ºBudapest, Hungary
Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia
ðŸ‡ðŸ‡ºBudapest, Hungary
The Hospital of Hyogo College of Medicine
🇯🇵Nishinomiya, Hyogo, Japan
National Hospital Organization Sendai Medical Center
🇯🇵Sendai, Miyagi, Japan
Donetsk National Medical University n.a M. Gorky, Faculty of Internal Medicine #2
🇺🇦Donetsk, Ukraine
West Coast Clinical Trials
🇺🇸Cypress, California, United States
Alliance Clinical Research
🇺🇸Oceanside, California, United States
Clinical Research Of The Rockies
🇺🇸Lafayette, Colorado, United States
Shands Endoscopy Center
🇺🇸Gainesville, Florida, United States
Shands Hospital at the University of Florida
🇺🇸Gainesville, Florida, United States
Shands Medical Plaza and Cancer Center
🇺🇸Gainesville, Florida, United States
Gastroenterology Group of Naples
🇺🇸Naples, Florida, United States
Gulfshore Endoscopy Center (Endoscopies Only)
🇺🇸Naples, Florida, United States
North Florida Gastroenterology Research, LLC
🇺🇸Orange Park, Florida, United States
Internal Medicine Specialists
🇺🇸Orlando, Florida, United States
Cotton-O'Neil Clinical Research Center, Digestive Health
🇺🇸Topeka, Kansas, United States
Cardiology Consultants
🇺🇸Norfolk, Virginia, United States
Metropolitan Gastroenterology Group, P C
🇺🇸Washington DC, Virginia, United States
Endoscopy Center of Tyler
🇺🇸Tyler, Texas, United States
Nepean Public Hospital
🇦🇺Kingswood, New South Wales, Australia
London Health Sciences Centre - University Hospital
🇨🇦London, Ontario, Canada
Universitaetsklinikum Schleswig-Holstein
🇩🇪Kiel, Germany
Medial Pharma spol.s.r.o. (Pharmacy only)
🇨🇿Hradec Králové, Czech Republic
Hopital Huriez CHRU de Lille
🇫🇷Lille Cedex, France
Osaka City University Hospital
🇯🇵Osaka, Japan
Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine
🇰🇷Seoul, Korea, Republic of
Peterfy Sandor Utcai Korhaz, Rendelointezet es Baleseti Kozpont, I. sz. Belgyogyaszat
ðŸ‡ðŸ‡ºBudapest, Hungary
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine
🇰🇷Seoul, Korea, Republic of
Parklands Medical Centre
🇿🇦Durban, South Africa
University of Utah HSC
🇺🇸Salt Lake City, Utah, United States
ACMG Endoscopy Center
🇺🇸Anaheim, California, United States
West Coast Endoscopy Center
🇺🇸Clearwater, Florida, United States
Clinical Research of West Florida, Inc.
🇺🇸Clearwater, Florida, United States
ACRI - Phase I, LLC
🇺🇸Anaheim, California, United States
Advanced Clinical Research Institute-Phase 1, LLC
🇺🇸Anaheim, California, United States
Investigational Drug Services - University Hospitals Case Medical Center
🇺🇸Cleveland, Ohio, United States
University Hospitals Case Medical Center
🇺🇸Cleveland, Ohio, United States
Gasteroenterology Consultants of Clearwater
🇺🇸Clearwater, Florida, United States
Gastroenterology Associates of Central Georgia, LLC
🇺🇸Macon, Georgia, United States
The Center for Digestive Health
🇺🇸Milwaukee, Wisconsin, United States
University of Florida - College of Medicine
🇺🇸Gainsville, Florida, United States
NYU Langone Nassau Gastroenterology Associates
🇺🇸Great Neck, New York, United States
Wisconsin Center for Advanced Research - GI Associates, LLC
🇺🇸Milwaukee, Wisconsin, United States
Office of Dr. David C. Pearson
🇨🇦Victoria, British Columbia, Canada
Office of Drs. Ranjith Andrew Singh and Jamie D. Papp,
🇨🇦Victoria, British Columbia, Canada
PerCuro Clinical Research Ltd.
🇨🇦Victoria, British Columbia, Canada
Kingsbury Hospital
🇿🇦Cape Town, Western Cape, South Africa
Metropolitan Gastroenterology Group, PC
🇺🇸Chevy Chase, Maryland, United States
Center for Digestive Health
🇺🇸Troy, Michigan, United States
East Ann Arbor Health and Geriatrics Center
🇺🇸Ann Arbor, Michigan, United States
Chevy Chase Endoscopy Center
🇺🇸Chevy Chase, Maryland, United States
Surgical Centers of Michigan
🇺🇸Troy, Michigan, United States
Hepato-Gastroenterologie HK, s.r.o.
🇨🇿Hradec Kralove, Czech Republic
Premier Medical Group of the Hudson Valley, PC
🇺🇸Poughkeepsie, New York, United States
Great Lakes Gastroenterology
🇺🇸Mentor, Ohio, United States
University of Michigan Health Systems
🇺🇸Ann Arbor, Michigan, United States
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Digestive Health Specialists of Tyler
🇺🇸Tyler, Texas, United States
Digestive & Liver Desease Specialists
🇺🇸Norfolk, Virginia, United States
AKH Wien Universitaetsklinik fuer Innere Medizin III
🇦🇹Wien, Austria
4 MBAL Parvo vatreshno otdelenie
🇧🇬Sofia, Bulgaria
Royal Melbourne Hospital
🇦🇺Melbourne, Australia
MBAL Sofiamed OOD, Otdelenie po gastroenterologia
🇧🇬Sofia, Bulgaria
Montreal General Hospital - McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
RDG centrum s.r.o. (Radiology only)
🇨🇿Hradec Kralove, Czech Republic
General Hospital of Athens "Evangelismos",1st Gastroenterology Department
🇬🇷Kolonaki Athens, Greece
Hôpital Haut-Lévêque/Service d hépato-gastroentérologie
🇫🇷Pessac Cedex, France
Charite - Campus Berlin Mitte
🇩🇪Berlin, Germany
Charite - Campus Benjamin Franklin
🇩🇪Berlin, Germany
Laboratorium Kft. Fovarosi és Pest Megyei Mikrobiologiai Laboratorium
ðŸ‡ðŸ‡ºBudapest, Hungary
Bugat Pal Korhaz Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.,
ðŸ‡ðŸ‡ºGyongyos, Hungary
Laboratórium Kft. Somogy Megyei Mikrobiológiai Laboratórium
ðŸ‡ðŸ‡ºKaposvár, Hungary
Clinfan Kft.
ðŸ‡ðŸ‡ºSzekszard, Hungary
Digestive Disease Institute
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel -Aviv, Israel
Toho University Sakura Medical Center
🇯🇵Chiba, Japan
Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital
🇯🇵Hokkaido, Japan
VU University Medical Center
🇳🇱Amsterdam, Netherlands
Academisch Medisch Centrum
🇳🇱Amsterdam, Netherlands
Comite Etico de Investigacion Clinica
🇪🇸Barcelona, Spain
Hospital Universitario de La Princesa
🇪🇸Madrid, Spain
Municipal Institution "Odesa Regional Clinical Hospital", Odesa Regional Centre of Gastroenterology.
🇺🇦Odesa, Ukraine
Medical Clinical Research Center of Medical Center "Health Clinic" LLC
🇺🇦Vinnitsa, Ukraine
Allegiance Research Specialists
🇺🇸Wauwatosa, Wisconsin, United States
GI Associates
🇺🇸Wauwatosa, Wisconsin, United States
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Charite, Universitaetsmedizin Berlin, Campus Virchow-Klinikum
🇩🇪Berlin, Germany
Universitaetsklinikum Ulm, Klinik Fuer Innere Medizin I
🇩🇪Ulm, Germany